Detail akcie Orthocell Rg online

Business Summary: Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Orthocell Ltd revenues increased 36% to A$9.2M. Net loss increased 19% to A$8.6M. Revenues reflect Regenerative medicine industry segment increase of 74% to A$5.2M. Higher net loss reflects Regenerative medicine industry segment loss increase of 15% to A$11.8M. Basic Earnings per Share excluding Extraordinary Items remained flat at -A$0.04.